Your browser is no longer supported. Please, upgrade your browser.
CNCE Concert Pharmaceuticals, Inc. daily Stock Chart
Concert Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.70 Insider Own1.00% Shs Outstand31.46M Perf Week-0.86%
Market Cap335.29M Forward P/E- EPS next Y-2.96 Insider Trans-5.68% Shs Float24.39M Perf Month12.49%
Income-71.10M PEG- EPS next Q-0.76 Inst Own73.30% Short Float2.92% Perf Quarter12.16%
Sales6.40M P/S52.39 EPS this Y-37.30% Inst Trans0.23% Short Ratio5.91 Perf Half Y7.46%
Book/sh4.58 P/B2.52 EPS next Y-6.90% ROA-43.90% Target Price- Perf Year88.09%
Cash/sh5.07 P/C2.27 EPS next 5Y- ROE-54.80% 52W Range5.47 - 13.09 Perf YTD24.99%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-77.80% 52W High-11.92% Beta0.82
Dividend %- Quick Ratio16.10 Sales past 5Y-34.00% Gross Margin- 52W Low110.79% ATR0.61
Employees70 Current Ratio16.10 Sales Q/Q12934.70% Oper. Margin- RSI (14)63.58 Volatility4.76% 5.88%
OptionableYes Debt/Eq0.00 EPS Q/Q47.40% Profit Margin- Rel Volume1.06 Prev Close11.51
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume120.28K Price11.53
Recom1.70 SMA208.37% SMA5012.64% SMA20016.83% Volume127,737 Change0.17%
Mar-30-20Initiated Jefferies Buy $23
Oct-03-19Reiterated H.C. Wainwright Buy $29 → $25
Jun-24-19Initiated SunTrust Buy $30
Jun-13-19Upgrade Janney Neutral → Buy
Jun-13-19Reiterated H.C. Wainwright Buy $26 → $29
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Oct-13-20 07:00AM  
Sep-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-18-20 06:00AM  
Aug-12-20 08:06AM  
Aug-06-20 11:05AM  
Jul-30-20 12:33PM  
Jul-08-20 07:00AM  
Jul-06-20 11:44AM  
Jun-30-20 12:00PM  
Jun-24-20 10:39AM  
Jun-12-20 04:01PM  
May-26-20 07:00AM  
May-22-20 08:52AM  
May-12-20 09:14PM  
May-01-20 12:30AM  
Apr-30-20 08:45AM  
Apr-29-20 12:00PM  
Apr-23-20 07:00AM  
Apr-15-20 08:55AM  
Apr-01-20 07:00AM  
Mar-26-20 11:54AM  
Mar-12-20 12:13AM  
Feb-24-20 07:00AM  
Feb-20-20 07:00AM  
Jan-30-20 04:01PM  
Jan-28-20 09:00AM  
Jan-27-20 04:02PM  
Jan-24-20 05:52AM  
Jan-22-20 08:40AM  
Dec-19-19 04:05PM  
Dec-16-19 05:54AM  
Dec-13-19 02:18PM  
Dec-02-19 07:00AM  
Nov-25-19 11:21PM  
Nov-12-19 07:00AM  
Nov-10-19 08:40AM  
Nov-07-19 08:15AM  
Nov-06-19 07:00AM  
Nov-05-19 01:36PM  
Oct-31-19 10:35AM  
Oct-12-19 03:15AM  
Oct-02-19 07:00AM  
Sep-27-19 11:48AM  
Sep-23-19 07:00AM  
Sep-19-19 10:32AM  
Sep-17-19 07:00AM  
Sep-12-19 07:00AM  
Aug-29-19 07:00AM  
Aug-27-19 12:17AM  
Aug-16-19 03:10PM  
Aug-06-19 05:12AM  
Aug-01-19 09:25AM  
Jul-25-19 07:00AM  
Jul-05-19 03:12PM  
Jun-13-19 05:05PM  
Jun-12-19 07:00AM  
Jun-05-19 07:00AM  
May-28-19 02:13PM  
May-16-19 07:00AM  
May-14-19 07:00AM  
May-07-19 01:51PM  
May-02-19 11:52AM  
Apr-29-19 07:00AM  
Apr-25-19 10:34AM  
Apr-11-19 09:46AM  
Apr-10-19 06:30AM  
Apr-08-19 03:09PM  
Mar-25-19 10:42AM  
Mar-12-19 08:13AM  
Mar-07-19 08:40AM  
Mar-06-19 07:00AM  
Mar-05-19 04:09PM  
Mar-01-19 07:00AM  
Feb-28-19 10:49AM  
Feb-21-19 07:00AM  
Feb-13-19 07:36AM  
Feb-12-19 08:00AM  
Feb-11-19 07:00AM  
Feb-05-19 02:25PM  
Jan-24-19 07:00AM  
Jan-22-19 07:00AM  
Jan-02-19 08:55AM  
Dec-19-18 11:39PM  
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUTT PETER BARTONDirectorAug 31Option Exercise3.793,53913,4137,963Sep 01 04:01 PM
Cassella James VChief Development OfficerAug 17Sale10.374,35445,15176,127Aug 19 05:44 PM
Becker Marc A.Chief Financial OfficerAug 17Sale10.242,87529,44053,434Aug 19 05:43 PM
Stuart NancyChief Operating OfficerJun 22Option Exercise3.7921,23880,492167,924Jun 24 09:02 AM
Stuart NancyChief Operating OfficerJun 22Sale11.3410,295116,694157,629Jun 24 09:02 AM
Tung Roger DChief Executive OfficerMar 13Option Exercise3.7914,60155,338752,758Mar 16 07:23 AM
Auchincloss Thomas GDirectorMar 12Buy8.521,50012,7736,500Mar 13 12:19 PM
Auchincloss Thomas GDirectorFeb 03Buy10.911,00010,9105,000Feb 04 11:30 AM
Stuart NancyChief Operating OfficerDec 04Option Exercise4.415,89626,001104,739Dec 06 04:05 PM
Tung Roger DChief Executive OfficerDec 04Option Exercise4.4113,16658,062644,686Dec 06 04:05 PM